Convergen Pharmaceuticals

Convergen Pharmaceuticals is a biotechnology company focused on developing therapies for diseases driven by pathological protein aggregates. The company is pioneering TrimTAC (TRIM21-targeting chimeras), a platform for next-generation bifunctional degraders that utilize the E3 ubiquitin ligase TRIM21 to selectively clear these harmful multimeric proteins. This approach addresses a significant gap in targeted protein degradation (TPD), as traditional methods have struggled to eliminate the pathogenic protein aggregates that are the root cause of many neurodegenerative diseases.

The company's scientific foundation is built upon the work of Dr. Ting Han, the Scientific Co-Founder, who is a recognized expert in protein degradation. Dr. Jinquan Sun is also a co-founder of Convergen. The company's business model is centered on leveraging its proprietary TrimTAC platform to develop a pipeline of therapies for neurodegenerative disorders and other diseases with high unmet medical needs. Revenue generation will likely be pursued through partnerships, licensing agreements, and the eventual commercialization of its therapeutic candidates.

In December 2025, Convergen announced the closing of a $10 million Seed financing round led by Qiming Venture Partners. These funds are intended to accelerate the development of the TrimTAC platform and advance its early pipeline towards clinical proof-of-concept. The company aims to address conditions with limited treatment options by combining academic research with industry experience in drug development.

Keywords: targeted protein degradation, neurodegenerative diseases, TrimTAC platform, bifunctional degraders, TRIM21, pathological protein aggregates, CNS drug development, protein degradation expert, seed financing, biotech